Billiontoone (NASDAQ:BLLN – Get Free Report) had its target price raised by JPMorgan Chase & Co. from $120.00 to $125.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 37.63% from the company’s current price.
Several other analysts have also weighed in on BLLN. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Billiontoone in a report on Friday, May 1st. BTIG Research dropped their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Finally, Guggenheim dropped their price objective on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 30th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and an average target price of $122.43.
Read Our Latest Stock Analysis on BLLN
Billiontoone Trading Up 11.6%
Billiontoone (NASDAQ:BLLN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same quarter last year, the company earned ($0.39) earnings per share. The business’s revenue was up 83.8% on a year-over-year basis. Analysts anticipate that Billiontoone will post 0.42 earnings per share for the current fiscal year.
Institutional Trading of Billiontoone
Hedge funds have recently modified their holdings of the stock. Rossby Financial LCC bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $76,000. Smartleaf Asset Management LLC bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $82,000. Finally, Renaissance Capital LLC bought a new position in Billiontoone in the fourth quarter valued at approximately $201,000.
About Billiontoone
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
See Also
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
